Interstitial Lung Disease

Given the rarity of pulmonary fibrosis, pulmonologists are constantly seeking to know more about the disease and advance research on treatment options.

The FDA granted orphan drug designation to zelasudil for treating patients with idiopathic pulmonary fibrosis, according to a press release from the drug’s manufacturer.

Nintedanib slows the deterioration of lung functionality in patients with limited cutaneous systemic sclerosis and interstitial lung disease, according to data published in Rheumatology.

The American College of Rheumatology “strongly recommends” against the use of glucocorticoids as a first-line therapy for interstitial lung disease in patients with systemic sclerosis-associated ILD, according to newly released guidelines.

AUSTIN, Texas — Ongoing communication between rheumatology and pulmonology is essential to managing “unpredictable” interstitial lung disease, according to a presenter at the 2023 Rheumatology Nurses Society annual conference.

Approximately 7% of patients with systemic sclerosis in an Australian cohort demonstrated concurrent pulmonary arterial hypertension and interstitial lung disease, according to data published in Arthritis Research & Therapy.

Inhaled treprostinil was safe in patients with pulmonary hypertension associated with interstitial lung disease over 1 year and sustained improved exercise capacity, according to study results published in European Respiratory Journal.

For individuals related to someone with familial interstitial pneumonia, the prevalence of pulmonary fibrosis was around 1,000 per 100,000 person-years, according to study results.

Dermatologists should be aware of cutaneous findings in patients with systemic sclerosis sine scleroderma due to the association of internal organ dysfunction, according to a study.